Clene Inc. (CLNN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Clene Inc. (NASDAQ: CLNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.83 (-1.79% 1D, market cap $55.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLNN ranks #718 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLNN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of -35.0%. By comparison, TLPH (Talphera Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M) and HRTX (Heron Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $55.9M). Among the 5-stock peer group, CLNN leads on earnings multiple (N/A) while CLNN leads on capital efficiency (-35.0% ROIC).
Per CLNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822791), Clene Inc. generated $200.0K in revenue (-41.5% YoY), -$26.2M in net income, and -$18.6M in free cash flow against $18.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 49.4 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CLNN currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.95) and Max Pain ($4.02) forces dealer call-delta covering toward $14.18.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Clene Inc. (CLNN) slipped -1.79% to $3.83, trading at 8% of its 52-week range ($3.02 – $13.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
3M shares rose 4.4% premarket after expanding its Amazon data-center deal, including a $521.4M stock warrant; other stocks saw sharp moves.
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage b
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -41.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CLNN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CLNN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Clene Inc. (CLNN) ranks #718 by composite RQD confidence (34/100, grade E) and #736 by equity capitalization ($55.4M). Within this direct 5-issuer industry benchmark cohort, CLNN leads on earnings valuation at N/A trailing P/E, while CLNN leads on capital efficiency and profitability with -35.0% ROIC and 78.5% gross margin. HYPD currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with CLNN at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CLNN
ACTIVE
Clene Inc. | E | 34/100 | — | 78.5% | -35.0% | -1.79% | $55.4M | Benchmark Subject |
| TLPH Talphera Inc. | D- | 42/100 | — | — | -35.0% | -3.74% | $55.5M | /tlph-vs-clnn → |
| HRTX Heron Therapeutics Inc. | D- | 37/100 | — | 73.3% | -35.0% | -5.67% | $55.9M | /hrtx-vs-clnn → |
| ONCY Oncolytics Biotech Inc. | D | 45/100 | — | — | -35.0% | -0.54% | $56.1M | /oncy-vs-clnn → |
| HYPD Hyperion DeFi Inc. | D | 50/100 | — | 62.7% | -35.0% | -8.13% | $54.1M | /hypd-vs-clnn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Clene Inc. (CLNN) reported GAAP revenue of $200.0K (-41.5% vs. FY2024 revenue of $342.0K , and -69.4% cumulative change since FY2023) , GAAP net income of -$26.2M, operating cash flow of -$18.5M, and free cash flow of -$18.6M (+12.9% YoY). On the balance sheet, CLNN closed FY2025 with $18.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $200.0K | -$26.2M | -$18.5M | -$18.6M | $18.1M | — |
| FY2024 (FY) | 2024-12-31 | $342.0K | -$39.4M | -$21.3M | -$21.3M | $27.3M | — |
| FY2023 (FY) | 2023-12-31 | $654.0K | -$49.5M | -$30.2M | -$30.2M | — | — |
As of 2026-11-02, Clene Inc. (NASDAQ: CLNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.83 (-1.79% 1D, market cap $55.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLNN ranks #718 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLNN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of -35.0%. By comparison, TLPH (Talphera Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M) and HRTX (Heron Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $55.9M). Among the 5-stock peer group, CLNN leads on earnings multiple (N/A) while CLNN leads on capital efficiency (-35.0% ROIC).
Per CLNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001822791), Clene Inc. generated $200.0K in revenue (-41.5% YoY), -$26.2M in net income, and -$18.6M in free cash flow against $18.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CLNN last traded at $3.83 (-1.79% on volume of 47,281 shares), positioning the stock -3.04% below its 50-day simple moving average ($3.95) and -26.06% below its 200-day simple moving average ($5.18). Across its 52-week range of $3.02 to $13.50, CLNN sits at the 7.7% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.35 to $4.31).
Why CLNN Stock slipped -1.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).